FindTrial
Sign In

A study on prescription patterns, adverse drug reactions and medication awareness in Schizophrenia patients

Evaluation of prescription patterns, adverse drug reactions and awareness of drug treatment in patients of Schizophrenia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/03/012533
Enrollment
360
Registered
2018-03-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Schizophrenia patients diagnosed as per DSM-V criteria and their caregivers Health Condition 2: F209- Schizophrenia, unspecified

Interventions

None listed

Sponsors

Seth GS Medcial College and KEM Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria for patients: 1. Male or female patients with age 18-65 years, attending Psychiatry OPD for existing Schizophrenia diagnosed as per DSM-V Criteria 2. Patients carrying treatment records prescribed at Psychiatry OPD of KEM Hospital, containing antipsychotic medication regimen for at least 3 months 3. For patients who will be given the drug awareness questionnaire, insight score equal to or above 9 on Birchwood insight scale thereby suggesting that patient has good insight Inclusion criteria for the caregivers: 1.Primary caregivers of the patient. 2. Those who give written informed consent

Exclusion criteria

Exclusion criteria: Exclusion Criteria for patients: 1.Patients admitted to psychiatry IPD and emergency department as well as referred patients 2. Newly diagnosed and treatment-naive patients 3.Patients with a history of Substance dependence or abuse at the current visit. 4.Patients with other Neurological disorders (dementia, delirium, and other cognitive disorders), seizure disorders, with sensory impairment and other psychiatric disorders such as mood disorders, and anxiety disorders. 5.Critically ill patients requiring urgent attention to medical problems Exclusion criteria for the caregivers: 1. Those with age 65 years 2. Those having neurological disorders such as dementia, delirium and other cognitive disorders

Design outcomes

Primary

MeasureTime frame
To study the awareness of drug treatment in Schizophrenic patients having insightTimepoint: Single point (cross sectional study), 18 months duration—

Secondary

MeasureTime frame
To study the awareness of drug treatment in Schizophrenic patients having insightTimepoint: Single point (cross sectional study), 18 months duration—

Countries

India

Contacts

Public ContactNishtha Khatri

Seth GS Medical College and KEM Hospital

nkhatri115@gmail.com9769155547

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026